Maze Therapeutics Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Maze Therapeutics Inc
Current Price
$25.56
-3.29%Profile
Valuation (TTM)
Market Cap$1.27B
P/E-10.37
EV—
P/B3.58
Shares Out49.71M
P/Sales63.53
Revenue$20.00M
EV/EBITDA—
Maze Therapeutics Inc (MAZE) Stock Analysis
Market Cap$1.27B
Current Price$25.56
P/E Ratio-10.37
Forward P/E—
PEG Ratio0.17
EPS$-3.05
Book Value$7.14
P/B Ratio3.58
MAZE Financial Charts
FCF vs CAPEX
FCFCAPEX
Cash vs Debt
Net Cash: 167M
Revenue
—
FY22
—
FY23
168M
FY24
—
FY25
Net Income
—
FY22
—
FY23
3M
FY24
—
FY25
MAZE 52-Week Range
$9.70
$51.84
50-Day MA: $33.02200-Day MA: $32.54
Did you know?
Price sits at 38% of its 52-week range.
Maze Therapeutics Inc (MAZE) Financial Summary
Maze Therapeutics Inc (MAZE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. The stock currently trades at $25.56 with a market capitalization of $1.27B.
Key valuation metrics include a P/E ratio of -10.37, price-to-book ratio of 3.58, and EPS of $-3.05. The company reports a profit margin of -612.7% and return on equity of -34.5%.
MAZE Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $1.27B |
| P/E Ratio | -10.37 |
| EPS | $-3.05 |
| P/B Ratio | 3.58 |
| P/S Ratio | 63.53 |
| Profit Margin | -612.7% |
| Return on Equity | -34.5% |
| Debt/Equity | 0.07 |
MAZE Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY22 | $0.00 | $-114.94M |
| FY23 | $0.00 | $-100.42M |
| FY24 | $167.50M | $3.40M |
| FY25 | $0.00 | $-131.12M |
MAZE Quality Indicators
Maze Therapeutics Inc maintains a profit margin of -612.7%. Return on equity stands at -34.5%. The current ratio is 15.50. Debt-to-equity ratio is 0.07.
About Maze Therapeutics Inc
Maze Therapeutics Inc
MAZE Free Cash Flow
Maze Therapeutics Inc generated $-112.73M in trailing twelve-month free cash flow, representing an FCF yield of -8.87%. This low FCF yield may reflect heavy reinvestment or growth spending.
MAZE Shares Outstanding
Maze Therapeutics Inc has 0.05 billion shares outstanding at a share price of $25.56, giving it a market capitalization of $1.27B.